-
After transformation under new CEO, Leo Pharma touts innovation model and financial progress
13 Mar 2024 00:34 GMT
… .
But under Bourdon’s watch, Leo Pharma is taking steps toward a … that the innovation model for Leo Pharma is accelerating,” Bourdon said in … is or has worked for Leo Pharma,” Bourdon said. “I took the …
-
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting
10 Mar 2024 22:29 GMT
… MEDIA
Timber Pharmaceuticals, Inc., a LEO Pharma company, today presents preliminary results … Meldgaard Madsen, Chief Development Officer, LEO Pharma. “We know that the management … initiated in Q2 2022.
About LEO Pharma
LEO Pharma is a global company dedicated …
-
LEO Pharma Unveils Late-Breaking Data for Landmark DELTA 3 Open-Label Extension Trial at the 2024 AAD Annual Meeting
09 Mar 2024 19:31 GMT
… Meldgaard Madsen, Chief Development Officer, LEO Pharma. “Having the opportunity to present … , where JT retains rights.
About LEO Pharma
LEO Pharma is a global company dedicated … therapies for all disease severities. LEO Pharma is headquartered in Denmark with …
-
LEO Pharma Presents New Long-Term Adbry® (tralokinumab-ldrm) Data in Adults with Moderate-to-Severe Atopic Dermatitis at the 2024 AAD Annual Meeting
08 Mar 2024 15:13 GMT
… and President, Region North America, LEO Pharma. “Following the expansion of our … and Instructions for Use.
About LEO Pharma
LEO Pharma is a global company dedicated … therapies for all disease severities. LEO Pharma is headquartered in Denmark with …
-
LEO Pharma to Maintain Leadership Role at AAD in 2024 with New Late-Breaking Data Spanning Multiple Therapeutic Areas
06 Mar 2024 13:15 GMT
… dermatology,” said Kreesten Meldgaard Madsen, LEO Pharma’s Chief Development Officer. “We … and President, Region North America, LEO Pharma. “The opportunity to collaborate and … initiated in Q2 2022.
About LEO Pharma
LEO Pharma is a global company dedicated …
-
Annual Report 2023: LEO Pharma Delivers 10% Revenue Growth and Returns to Positive EBITDA
29 Feb 2024 13:14 GMT
… and increasing interest expenses.
LEO Pharma exceeded our profitability guidance and … Exchange Rates (CER)
About LEO Pharma
LEO Pharma is a global company dedicated … please visit:
Our annual reporting | LEO Pharma (leo-pharma.com)
1 EBITDA adjusted for …
-
Liver disease incidences from bimekizumab low among patients with psoriasis
18 Apr 2024 19:09 GMT
… , Janssen Research & Development LLC, LEO Pharma, Meiji Seika Pharma, Mindera, Ortho …
-
VIDEO: At-home phototherapy ‘noninferior’ to in-office treatment for psoriasis
18 Apr 2024 19:09 GMT
… , Galderma, Genentech, GSK, Incyte, Janssen, LEO Pharma, L’Oréal, Nektar Therapeutics, Opsidio …
-
Skin Cancer Drugs Market See Incredible Growth worldwide 2024-2031 | Valeant, Daiichi Sankyo, Takeda, LEO Pharma
23 Feb 2024 07:55 GMT
… ; Johnson
✤ Valeant
✤ Daiichi Sankyo
✤ Takeda
✤ LEO Pharma
✤ Mylan
✤ Sanofi
✤ Regeneron
✤ Eli Lilly …
-
LEO Pharma acquires Timber Pharmaceutical’s bankruptcy assets including TMB-001
24 Jan 2024 17:51 GMT
… to LEO Pharma.
Following the bankruptcy of Timber Pharmaceuticals, LEO Pharma has … bankruptcy of Timber Pharmaceuticals, LEO Pharma has finalized the acquisition of … Timber Pharmaceuticals to LEO Pharma,” Christophe Bourdon, CEO of LEO Pharma, said in …